Dundalk, Tánaiste and Minister for Enterprise, Trade and Employment, Mary Coughlan T.D, today (Wednesday February 24th) announced that Warner Chilcott plc, a global pharmaceutical company listed on NASDAQ, is to establish a new headquarters in Dundalk, Co. Louth, which has the potential to create up to 200 high-skilled positions in the coming years. The investment is supported by the Irish Government through IDA Ireland.
Warner Chilcott’s location in Dundalk is expected to house a host of functions, which may include executive offices, analytical services, manufacturing operations and shared services to support Warner Chilcott’s operations in the EU.
Warner Chilcott, a global specialty pharmaceutical company, currently focuses on the gastroenterology, women's healthcare, dermatology and urology segments of the U.S. and Western European pharmaceuticals markets. Since being spun out of Warner-Lambert in 1996, Warner Chilcott has evolved through a series of acquisitions and divestitures from a small seller of undifferentiated products to a fully integrated pharmaceutical company with a broad portfolio of leading branded products.
Speaking at the announcement, Tánaiste and Minister for Enterprise, Trade and Employment, Mary Coughlan T.D. said: “I am delighted that Warner Chilcott has chosen Dundalk for this important operation. This development is excellent news for the North-East region and Ireland as a whole. Dundalk is one of Ireland’s busiest economic corridors, between Dublin and Belfast, and today’s announcement will bring new high quality employment opportunities to the region, adding further to the regions portfolio of world class Foreign Direct Investment companies operating here which include Xerox, Heinz, Moffett, Diageo, ABB, National Pen and Satir”.
Speaking on behalf of the company Roger Boissonneault, Warner Chilcott’s President and Chief Executive Officer, said: “We are excited to establish a new headquarters in Dundalk and are delighted with the support being provided by IDA Ireland. We anticipate that the new facility will play an integral role in the growth of our business.”
Notes to Editor
About Warner Chilcott
Warner Chilcott is a global specialty pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology and urology segments of the U.S. and Western European pharmaceuticals markets. Since being spun out of Warner-Lambert in 1996, Warner Chilcott has evolved, through a series of acquisitions and divestitures, from a small seller of undifferentiated products to a fully integrated pharmaceutical company with a broad portfolio of leading branded products. The acquisition of The Procter & Gamble Company's global branded pharmaceuticals business on October 30, 2009 transformed Warner Chilcott into a global pharmaceuticals company with significant scale and geographic reach. Today, Warner Chilcott has an expanded sales force and infrastructure to better promote products in the U.S., major Western European and other markets, increased diversity of revenue sources, enhanced product development capabilities and a deeper product development pipeline.
Headquartered in Ardee, Ireland, Warner Chilcott has employees in 12 countries in North America and Western Europe. The Company's manufacturing facilities are located in Puerto Rico, Northern Ireland and Germany. Warner Chilcott is listed on the Nasdaq Stock Exchange and trades under the symbol WCRX.
Thomas McEvoy, Press Manager Tel: +353 (0)1 6034255, Mob: +353 (0) 87 7426684
Antoinette Tyrrell, Press Officer, Tel: +353 (0)1 603 4256, Mob: +353 (0) 87 7572053
Department of Enterprise, Trade and Employment
Roisin McCann, Tel: +353 (0) 1 631 3333, Mob: +353 (0) 87 259 4144